Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SJ in connection with agreement governing restoration of SJ 2000 trains
Mandate

Vinge advises SJ in connection with agreement governing restoration of SJ 2000 trains

January 16, 2014

SJ is making one of the largest commitments in the company’s 150-year history by investing in a comprehensive renewal and restoration programme for its fleet of SJ 2000 trains. SJ has entered into an agreement with ABB concerning the initial technical restoration of the entire fleet of SJ 2000 trains (previously X 2000). This phase of the renovation will cost approximately SEK 1.4 billion. The first newly-renovated SJ 2000 train will be put into operation in 2016, although the renewal and restoration programme will continue until 2019. The renovation is anticipated to reduce energy consumption by approximately 10 per cent.

Vinge’s team consisted of, among others, partners Eva Fredrikson and Björn Gustavsson and associate Mikael Satama Grönberg.   

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024